- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04640935
Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC. (AVATAX)
Retrospective Multicenter Study of Paclitaxel in Combination With Bevacizumab in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC).
Visão geral do estudo
Status
Condições
Descrição detalhada
Lung and bronchopulmonary cancer is the leading cause of cancer death in France and worldwide. It is diagnosed at the metastatic stage from the outset in approximately 50% of cases. Non-small cell lung cancers (NSCLC) are the most frequent histological forms of lung cancer (approximately 85% of cases) with a predominance of the non-epidermal type.
The increase in the number of treatments available, improved supportive care and better patient selection have, in recent years, made it possible to expand the range of first-line chemotherapy treatments available at delà̀ and have contributed to the increase in overall survival (OS). As a result, nearly 80% of patients with metastatic NSCLC receive a second line of treatment. The main objective in these often symptomatic patients is a satisfactory tumor control rate with acceptable tolerability.
For a long time, the second-line reference chemotherapy has been docetaxel or pemetrexed as monotherapy with modest results. Alternative treatments such as the combination of paclitaxel (chemotherapy)-bevacizumab (anti-angiogenic monoclonal antibody) have been studied. Since 2010, by analogy with breast cancer and in the absence of therapeutic alternatives, the paclitaxel-bevacizumab doublet has been used in non-epidermal stage IV NSCLC in France. The value of combining taxane chemotherapy with an anti-angiogenic molecule has been demonstrated in two Phase 3 clinical trials. Thus, this combination is an integral part of the possible treatments in 2nd line and beyond, registered since 2016 in the treatment guidelines for non-epidermal NSCLC.
The first-line therapeutic strategy will also be redefined in 2019 with the use of immunotherapy for a majority of patients. Subsequent treatment lines will be modified, with a focus on chemotherapy, in particular the paclitaxel-bevacizumab combination.
As this combination has been used in current practice for several years, and in view of the upcoming changes to the first and second line of NSCLC treatment, data on the efficacy and tolerance of this combination in real life are needed to guide our practices. Recent studies are also looking at the efficacy of chemotherapy, particularly taxane chemotherapy associated with an anti-angiogenic agent after a previous line including immunotherapy, with a favorable signal.
The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Boulogne Billancourt, França
- Hopital Ambroise Pare Ap-Hp
-
Brest, França
- Centre Hospitalier Universitaire Brest
-
Chambéry, França
- Centre Hospitalier Metropole Savoie
-
Créteil, França
- Centre Hospitalier Intercommunal de Créteil
-
Grenoble, França
- Centre Hospitalier Universitaire Grenoble Alpes
-
Le Chesnay, França
- Centre Hospitalier de Versailles André Mignot
-
Lille, França
- Centre Hospitalier Universitaire de Lille
-
Lyon, França
- Hospices Civils de Lyon
-
Lyon, França
- Centre Leon Berard Lyon
-
Mantes-la-Jolie, França
- Centre Hospitalier François Quesnay
-
Metz-Tessy, França, 74374
- Centre Hospitalier Annecy Genevois
-
Paris, França
- Institut Curie
-
Saint-Cloud, França
- Institut Curie Saint Cloud
-
Saint-Étienne, França
- Institut de Cancérologie Lucien Neuwirth
-
Suresnes, França
- Hôpital Foch
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- At least 18 years old;
- Histologically or cytologically confirmed diagnosis of non-epidermal NSCLC;
- Advanced stage IV disease at the start of treatment with paclitaxel-bevacizumab according to TNM 7/8th edition classification;
- Treatment with paclitaxel-bevacizumab received as second-line therapy or beyond, in a clinical trial or not;
- Alive patients not opposed to the use of their data
Exclusion Criteria:
- Patient under guardianship or curatorship at the date of the study ;
- Patients alive at the time of the study who are opposed to the use of their data
- Opposition to the use of their data expressed during the lifetime of patients who died at the time of the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free survival
Prazo: Up to 12 months
|
Progression-free survival with paclitaxel-bevacizumab, i.e., the time from the start of paclitaxel-bevacizumab treatment to cancer progression, estimated at 12 months in the general population.
|
Up to 12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Drugs administration dosage description
Prazo: Up to 12 months
|
Description of the different monthly drug administration regimens
|
Up to 12 months
|
|
Objective response rate and control rate
Prazo: Up to 12 months
|
Objective response rate and control rate according to RECIST 1.1 criteria in the general population
|
Up to 12 months
|
|
Overall survival Rate
Prazo: Up to 12 months
|
Overall survival, assessed on the whole population
|
Up to 12 months
|
|
Objective Response Rate
Prazo: Up to 12 months
|
Objective Response Rate in the following subgroups:
|
Up to 12 months
|
|
Progression-Free Survival Rate
Prazo: Up to 12 months
|
Progression-Free Survival in the following subgroups:
|
Up to 12 months
|
|
Disease Control Rate
Prazo: Up to 12 months
|
Disease Control in the following subgroups:
|
Up to 12 months
|
|
Overall Survival Rate
Prazo: Up to 12 months
|
Overall Survival in the following subgroups:
|
Up to 12 months
|
|
Frequency of safety events
Prazo: Up to 12 months
|
Frequency of grade ≥3 adverse events and frequency of discontinuation of paclitaxel-bevacizumab for toxicity ;
|
Up to 12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Chantal Decroisette, CH Annecy Genevois
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 19-09
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .